Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Life Insurance Restarts Takeover Battle for iKang

publication date: Jun 17, 2016
The takeover battle for China health clinic operator iKang is back on, according to an article in Caixin. China Life Insurance is offering slightly more than $20 per share for iKang, the online business publication said. Previously China Life was bidding for iKang as part of a syndicate that included iKang's management and Yunfeng Capital, a private equity firm co-founded by Alibaba's Jack Ma. Two weeks ago, Yunfeng seemed to have won the fight by breaking away from the syndicate and offering $20-$25 per ADS on its own. The other two bidding groups backed away, rather than take on Yunfeng. More details....

Stock Symbols: (NSDQ: KANG) (NYSE: BABA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital